Biopharmaceutical firm Arrowhead Pharmaceuticals has signed a license and collaboration agreement with Janssen Pharmaceuticals for the development and commercialization of hepatitis B virus (HBV) treatment, ARO-HBV.
Boston Pharmaceuticals has signed a licensing and equity agreement with Novartis for the worldwide rights to three of the latter's anti-infective candidates for the potential treatment of Gram-negative infections.
Gilead firm Kite and HiFiBiO Therapeutics have entered into a research collaboration and license agreement to develop technology for the discovery of neoantigen-reactive T cell receptors (TCRs) to treat various cancers such as solid tumors.
Us biopharma company Kala Pharmaceuticals has closed a $110m credit facility with funds managed by healthcare focused investment firm Athyrium Capital Management.
GO Therapeutics has signed a license agreement with Roche for new glycotargeting bispecific cancer treatment.
KSQ Therapeutics has secured $80m series C financing to advance oncology drug candidates generated from its CRISPRomics drug discovery engine into clinical studies.
Janssen Biotech has ceased the collaboration and license agreement (CLA) with biopharmaceutical firm Geron for experimental cancer drug imetelstat.
Midatech Pharma has agreed to sell Midatech Pharma US to Kanwa Holdings, an investment vehicle affiliated with Barings, for total consideration of up to $19m.
Alexion Pharmaceuticals has agreed to acquire US-based clinical-stage biotechnology firm Syntimmune in a deal valued at around $1.2bn.
Opiant Pharmaceuticals has entered into a multi-year contract with potential funding up to a maximum of approximately $4.6m, with the Biomedical Advanced Research and Development Authority (BARDA) to accelerate the development of its lead product candidate OPTN003.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.